Despite overall progress in global TB control, the rising burden of multidrug-resistant TB
(MDR-TB) threatens to undermine efforts to end the worldwide epidemic. Of the 27 countries …

Introduction: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-and XDR-
TB) are major public health concerns worldwide. Their association with HIV/AIDS infection …

Tuberculosis (TB) remains a global emergency and is responsible for 1.7 million deaths
annually. Widespread global misuse of isoniazid and rifampicin over three decades has …

Background: In the Nix-TB trial, a six-month BPaL regimen, starting with 1200 mg linezolid
daily, resulted in 89% durable cure at 24 months post therapy follow-up, but a high rate of …

New treatments for multidrug-resistant tuberculosis (MDR TB) are urgently needed. Two new
drugs, bedaquiline and delamanid, have recently been released, and several new drugs …

Background In Africa, fewer than half of patients receiving therapy for multidrug-resistant TB
(MDR TB) are successfully treated, with poor outcomes reported for HIV-coinfected patients …

Objectives We aimed to assess the effect of second-line anti-TB treatment and determine
which drugs can achieve the greatest clinical benefit for DR-TB-HIV patients by comparing …

Two new drugs—bedaquiline and delamanid—have recently been approved by stringent
regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the …

BACKGROUND: Bedaquiline (BDQ) has not been extensively studied among patients co-
infected with HIV drug-resistant tuberculosis (DR-TB). We compared treatment outcomes in …

Background This retrospective cohort study assessed benefits and risks of bedaquiline
treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating …